Search for a trial

A pilot study on oral esketamine for depression and demoralization in patients with advanced cancer receiving palliative care

Evaluation of the feasibility of a trial on the efficacy of oral esketamine for the treatment of depression and/or demoralization in patients with advanced cancer who receive palliative care.

An open-label study to investigate the safety, tolerability, and Pharmacokinetics/Pharmacodynamics of risdiplam (RO7034067) in adult and pediatric patients with spinal muscular atrophy

This study has been transitioned to CTIS with ID 2023-506739-14-00 check the CTIS register for the current data. Primary ObjectivesThe primary objectives of this study are as follows:• To evaluate the safety and tolerability of risdiplam.• To…

A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia
Study ITCC-059

This study has been transitioned to CTIS with ID 2023-504694-20-00 check the CTIS register for the current data. - The primary objective of the Stratum 1A cohort is to establish the maximum tolerated dose of single agent InO when administered in…

A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

This study has been transitioned to CTIS with ID 2022-502526-41-00 check the CTIS register for the current data. Objective- To evaluate anti-tumor activity of pembrolizumab (MK-3475) by evaluating the absence of high risk NMIBC or progressive…

A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects with Crohn's Disease

This study has been transitioned to CTIS with ID 2024-510727-19-00 check the CTIS register for the current data. The primary objective of this study is to observe the long-term efficacy, safety, and tolerability of repeated administration of…

[18F]mFBG PET-CT imaging of pheochromocytoma

This study has been transitioned to CTIS with ID 2024-513622-35-00 check the CTIS register for the current data. The primary objective of this study is to assess the number of detected pheochromocytoma lesions, proved by histology, with [18F]mFBG…

A phase II trial of [177]Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma

This study has been transitioned to CTIS with ID 2023-503684-42-00 check the CTIS register for the current data. Main Study Objective• To confirm the dose and assess response to single agent 177Lutetium-DOTATATE treatmentin patients with relapsed or…

Access to Pirfenidone Solution for Inhalation (AP01) for Treatment of Progressive, Fibrosing Interstitial Lung Diseases, including Idiopathic Pulmonary Fibrosis

This study has been transitioned to CTIS with ID 2024-515964-30-00 check the CTIS register for the current data. • Allow patients to continue or start AP01 therapy for the treatment of ILD and IPF prior to regulatory approval or until the study is…

An Open-Label Pilot Study of Losmapimod to Evaluate the Safety, Tolerability, and Changes in Biomarker and Clinical Outcome Assessments in Subjects With Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) with Extension

This study has been transitioned to CTIS with ID 2024-512736-29-00 check the CTIS register for the current data. Primary Objective1. To evaluate the safety and tolerability of long-term dosing of losmapimod tablets in subjects with FSHD1Secondary…

CXCR4-directed [68Ga]Ga-PentixaFor PET/CT vs AVS performance in a diagnoStic randomized Trial Ultimately comparing hypertenSion outcome in primary aldosteronism

This study has been transitioned to CTIS with ID 2024-512628-12-00 check the CTIS register for the current data. Primary objectives-To assess the concordance between [68Ga]Ga-PentixaFor PET/CT and AVS for identification and/or lateralization of APAs…

Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response

This study has been transitioned to CTIS with ID 2024-513074-22-00 check the CTIS register for the current data. Primary Objective:The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with…

A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma

This study has been transitioned to CTIS with ID 2022-501076-26-00 check the CTIS register for the current data. Primary objective:• To evaluate the 2-year disease free survival (DFS)Secondary objectives:• To evaluate toxicity and asses the relation…

An Open-Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM).

This study has been transitioned to CTIS with ID 2023-508963-58-00 check the CTIS register for the current data. Primary: To determine the safety and tolerability of CK­3773274 in patients with symptomatic HCMSecondary: Assess long-term effects of…

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents With or Without Pembrolizumab in Participants with PD-1/L1 Refractory Locally Advanced or Metastatic Urothelial Carcinoma (KEYMAKER-U04): Substudy 04A

This study has been transitioned to CTIS with ID 2023-506384-34-00 check the CTIS register for the current data. Primary:- To assess the safety and tolerability of MK2140- To evaluate objective response rate (ORR) of MK2140 as assessed by BICR per…

Groningen International Study on Sentinel nodes in Vulvar cancer - III, a prospective phase II treatment trial

This study has been transitioned to CTIS with ID 2023-508722-99-00 check the CTIS register for the current data. Primary objective:- Investigate the safety of replacing inguinofemoral lymphadenectomy by chemoradiation in early stage vulvar cancer…

A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients with KIT altered hematologic malignancies

This study has been transitioned to CTIS with ID 2023-510144-20-00 check the CTIS register for the current data. The current study is designed to evaluate the preliminary safety and efficacy of BLU-263 in patients with AdvSM, including in those with…

A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of rilvegostomig (AZD2936) Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non-small Cell Lung Cancer (ARTEMIDE-01)

This study has been transitioned to CTIS with ID 2023-508262-15-00 check the CTIS register for the current data. Part D dose expansion:- To assess safety and tolerability of AZD2936 (rilvegostomig) in CPI-naive participants with stage IV NSCLC with…

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

This study has been transitioned to CTIS with ID 2023-503905-12-00 check the CTIS register for the current data. The main objectives for this study are: - To assess the safety and tolerability of the combination of pembrolizumab and lenvatinib and…

Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors

This study has been transitioned to CTIS with ID 2024-514962-38-00 check the CTIS register for the current data. -To assess the safety and tolerability of CLDN6 CAR-T +/- CLDN6 RNALPX and to assess the comparability of CLDN6 CAR-T from the manualand…

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

This study has been transitioned to CTIS with ID 2023-505034-10-00 check the CTIS register for the current data. To determine the objective response rate of entrectinib, as assessed by BICR, in each patient population basket of solid tumors that…